Skip to main content

Table 1 Clinical, hemodynamic and pulmonary parameters in the prevalent and incident populations

From: Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry

  Prevalent cases n = 100 Incident cases n = 91 p
Female sex, n (%) 65 (65.0) 60 (65.9) 0.892
NYHA FC    0.229
I + II, n (%) 34 (34.0) 21 (23.1)
III, n (%) 64 (64.0) 67 (73.6)
IV, n (%) 2 (2.0) 3 (3.3)
Age * (years) 47.0 (17.0) 47.8 (34.5–60.7/19.4–73.8) 57.3 (15.1) 59.8 (48.9–68.8/27.4–75.7) <0.001
BMI * (kg/m2) 26.2 (5.4) 26.0 (21.8–29.7/18.3–35.9) 27.8 (6.3) 26.5 (23.2–31.9/19.5–37.9) 0.100
6MWD * (m) 332.4 (123.0) 356.0 (246.0–420.0/150.0–511.0) 314.0 (117.0) 332.5 (239.0–403.0/128.0–474.0) 0.313
RAP * (mmHg) 10.0 (5.3) 9.0 (7.0–12.0/3.0–20.0) 9.8 (5.2) 9.0 (6.0–12.0/2.0–21.0) 0.934
mPAP * (mmHg) 65.8 (84.8) 56.5 (46.0–66.0/32.0–89.0) 51.8 (19.7) 47.0 (37.0–64.0/27.0–91.0) 0.004
PASP * (mmHg) 88.2 (24.6) 91.0 (70.0–103.0/45.0–134.0) 80.7 (28.5) 77.0 (58.0–97.0/40.0–132.0) 0.017
PCWP * (mmHg) 10.5 (3.2) 11.0 (8.0–13.0/5.0–15.0) 11.9 (3.1) 12.0 (10.0–15.0/7.0–15.0) 0.003
Cardiac index * (l/min/m2) 1.9 (0.7) 1.7 (1.3–2.4/0.8–3.3) 2.4 (0.8) 2.4 (1.9–2.9/1.1–3.9) <0.001
CO * (l/min) 3.4 (1.5) 3.2 (2.3–4.3/1.6–6.4) 4.3 (1.6) 3.9 (3.2–5.4/2.1–7.1) <0.001
SvO 2 * (%) 92.5 (5.5) 94.5 (90.2–96.4/78.0–98.1) 91.7 (6.8) 93.5 (89.9–96.2/79.0–98.0) 0.461
SvO 2 * (%) 66.4 (7.5) 66.0 (61.0–72.0/55.8–78.7) 70.0 (8.6) 72.0 (64.6–76.0/56.0–81.2) 0.002
LVEF * (%) 60.9 (8.4) 61.5 (55.0–67.0/46.0–74.0) 59.3 (7.5) 58.0 (55.0–64.0/45.0–72.0) 0.199
PAR * (WU) 20.1 (31.1) 16.0 (9.3–21.4/4.2–42.2) 10.8 (7.1) 8.5 (5.6–15.2/3.0–25.8) <0.001
S-creatinine * (μmol/l) 95.3 (43.1) 88.7 (71.6–99.0/59.1–173.5) 97.2 (49.8) 81.2 (71.0–104.0/56.0–193.0) 0.895
Creatinine clearance * (ml/min) 90 (30) 84 (66–108/42–144) 78 (36) 78 (60–96/30–138) 0.186
  1. NYHA, New York Heart Association; BMI, body mass index; 6MWD, 6-minute walk distance; RAP, resting arterial pressure; mPAP, mean pulmonary arterial pressure; PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; SaO2,oxygen saturation of arterial blood; SvO2, oxygen saturation of central venous blood; LVEF, left ventricular ejection fraction; PAR, pulmonary arteriolar resistance; CO, cardiac output.
  2. *Mean (SD), median (25th–75th/5th–95th percentile).
  3. Mann–Whitney U test for continuous parameters; maximal likelihood chi-square test or Fisher’s exact test for categorical parameters. P-value represents significance of NYHA FC between incident and prevalent cases.